2013 ESH/ESC Guidelines for the management of arterial hypertension

June 14, 2013

Lifestyle factors, lack of awareness by both patients and physicians, hesitancy in initiating and intensifying drug treatment, and healthcare structural deficiencies are amongst the reasons for the increasing problem of high blood pressure in Europe, according to new joint Guidelines issued today by the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). The Guidelines, which recommend several significant changes to hypertension treatment, are launched* today at the European Society of Hypertension congress in Milan, Italy, with simultaneous online publication in the peer-reviewed journals Journal of Hypertension, the European Heart Journal, and Blood Pressure .

First produced in 2003, the original version of the joint ESH/ESC Guidelines for the management of , became one of the most highly-cited medical papers in the world. The 2013 Guidelines – which replace the 2007 edition – give state of the science recommendations which show how the landscape has changed, and indicate what needs to be done to reduce mortality and morbidity from and associated conditions.

Hypertension has been described as "the leading global risk for mortality in the world"1. It continues to affect between 30 and 45% of the . The authors of the Guidelines express disappointment that this figure has remained high since the 2003 edition. "We really need to raise awareness of the condition", said Professor Giuseppe Mancia (Milan, Italy). This is a condition that can be controlled if treated properly."

According to the report, " are the cornerstone for the prevention of hypertension", including reduction of salt (to roughly half present levels) and alcohol, as well as maintaining a healthy body weight, regular exercise, and the elimination of smoking2.

Additionally, patients and doctors must be aware that once hypertension has developed, it can be treated with drug therapy. The Guidelines highlight the lack of awareness of the potential problems of hypertension amongst patients, with poor long-term adherence to treatment, and the "inertia" of doctors, who don't take appropriate action when confronted with patients with uncontrolled blood pressure.

The authors state that "despite overwhelming evidence that hypertension is a major cardiovascular risk, studies show that many are still unaware of the condition, that target blood pressure levels are seldom achieved". They also note that there are wide variations in hypertension care in Europe, but that team-based care, with greater nurse involvement, has a better record of success that more standard care3.

The 2013 reviewed all relevant data since the last revision (in 2007), with 18 specific diagnostic and therapeutic areas identified as containing significant change.

A major development is the decision to recommend a single systolic blood pressure target of 140 mmHg for almost all patients. This contrasts with the 2007 version which recommended a 140/90 mmHg target for moderate to low risk patients, and 130/80 mmHg target for high risk patients. "There was not enough evidence to justify two targets" said Professor Robert Fagard (Leuven, Belgium).

Other changes include:

  • An increasing role for home blood pressure monitoring, alongside ambulatory blood pressure monitoring4
  • A greater emphasis on assessing the totality of risk factors for cardiovascular and other diseases. For example, most people with hypertension also have additional risk factors such as organ damage, diabetes, and other cardiovascular risk factors. These need to be considered together before initiating treatment, and during the follow-up5
  • Special emphasis on specific groups, e.g. diabetics, the young, the elderly, and drug treatment of the over 80s. Women are also considered separately, e.g. during pregnancy. Special consideration is given to new treatments such as renal denervation for resistant hypertension – which is described as "promising", although more trials are called for6
  • New guidance on how and when to take anti-hypertensive drugs. The report indicated no treatment for high normal blood pressure, no specific preference for single drug therapy, and an updated protocol for drugs taken in combination. The guidance takes a liberal attitude to choice of first step drugs, noting the evidence that the beneficial effect of hypertension depends largely on lowering. Rather than presenting a hierarchy of drugs (a generic 1st, 2nd, 3rd choice and so on), the approach taken promotes individualized treatment, i.e. to help physicians to decide which drugs to give in which clinical/demographic condition7

The Guideline was developed over an 18 month period. Task Force members from both societies met several times to finalise the content, which was reviewed twice by a group of 40 European reviewers in addition to the internal reviewers. Both the ESC and the ESH appointed Task Force Chairs, who worked together to coordinate the Guideline development. For the first time, the Guidelines have graded the evidence according to class of the recommendation and the level of evidence. The final document will be simultaneously published in the peer-reviewed journals Journal of Hypertension, Blood Pressure and European Heart Journal

Commenting, Professor Giuseppe Mancia, Co-Chairperson of the Guidelines Task Force said: "This is certainly the most important current overview to consider the totality of hypertension treatment; it will form the basis of hypertension care for the foreseeable future. The WHO has already recognised hypertension as the leading global risk for mortality in the world, and as we identified in the document, the public needs to be more aware of just how common hypertension is. Not only that, doctors and patients need to recognise that we have good treatments which can control hypertension".

Professor Robert Fagard, Co-Chairperson of the Guidelines Task Force commented: "We are very happy to publish these comprehensive evidence-based Guidelines. It's the right time to carry out this revision, as we are able to include many significant studies and many new results since the previous version. We have included many of the gold standard randomized controlled trials (RCT) studies, but at the same time we have graded all the evidence so that clinicians can see how strong the evidence base is for each recommendation. The important thing now is for physicians put these recommendations into use".

Explore further: ESC recommends patients and centres for renal denervation

Related Stories

ESC recommends patients and centres for renal denervation

April 25, 2013
Up to 10 per cent of patients with high blood pressure are resistant to treatment, which puts them at increased risk of cardiovascular events, including heart attacks. Clinical trials show that catheter-based renal denervation ...

Pen on the pulse: A better way to measure blood pressure

May 28, 2013
(Medical Xpress)—In a world-first study, researchers from The University of Queensland are using innovative pulse-reading technology to measure blood pressure to reduce cardiovascular disease.

Common treatment for mild hypertension challenged

August 15, 2012
Doctors often prescribe drugs for people with mild high blood pressure with the hope of preventing cardiovascular disease (CVD). However, a new review from The Cochrane Library has found that this treatment does not reduce ...

Patients with type 2 diabetes or hypertension must be evaluated for sleep apnea

June 3, 2013
The American Academy of Sleep Medicine (AASM) is advising anyone with Type 2 diabetes or hypertension to be evaluated for sleep apnea by a board-certified sleep medicine physician. The recommendation comes as the group of ...

Volunteering reduces risk of hypertension in older adults, research shows

June 13, 2013
It turns out that helping others can also help you protect yourself from high blood pressure.

Renal denervation achieves significant and sustained blood pressure reduction

August 27, 2012
Renal denervation leads to significant and sustained blood pressure reduction for up to 18 months in patients with treatment resistant hypertension, according to research presented at ESC Congress 2012. The new clinical data ...

Recommended for you

Could aggressive blood pressure treatments lead to kidney damage?

July 18, 2017
Aggressive combination treatments for high blood pressure that are intended to protect the kidneys may actually be damaging the organs, new research from the University of Virginia School of Medicine suggests.

Quantifying effectiveness of treatment for irregular heartbeat

July 17, 2017
In a small proof-of-concept study, researchers at Johns Hopkins report a complex mathematical method to measure electrical communications within the heart can successfully predict the effectiveness of catheter ablation, the ...

Concerns over side effects of statins stopping stroke survivors taking medication

July 17, 2017
Negative media coverage of the side effects associated with taking statins, and patients' own experiences of taking the drugs, are among the reasons cited by stroke survivors and their carers for stopping taking potentially ...

Study discovers anticoagulant drugs are being prescribed against safety advice

July 17, 2017
A study by researchers at the University of Birmingham has shown that GPs are prescribing anticoagulants to patients with an irregular heartbeat against official safety advice.

Protein may protect against heart attack

July 14, 2017
DDK3 could be used as a new therapy to stop the build-up of fatty material inside the arteries

Heart study finds faulty link between biomarkers and clinical outcomes

July 14, 2017
Surrogate endpoints (biomarkers), which are routinely used in clinical research to test new drugs, should not be trusted as the ultimate measure to approve new health interventions in cardiovascular medicine, according to ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.